We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Guideline‑Level Moderate–Vigorous Physical Activity Appears Safe and Beneficial for Phenotype‑Negative Car cardiomyopathy Variant Carriers

MedXY Editorial Team•Nov 25, 2025•Cardiology
accelerometercardiomyopathygeneticsPhysical Activity

Highlights

Key points

– In 84,699 UK Biobank participants (3,979 G+P- carriers) with 1‑week accelerometer data and 8 years median follow-up, higher moderate‑to‑vigorous physical activity (MVPA) was associated with lower incidence of atrial fibrillation (AF), heart failure (HF), myocardial infarction (MI), and stroke, regardless of genotype.
– For G+P- carriers, MVPA of roughly 100–400 minutes per week associated with the lowest risk estimates for major cardiovascular outcomes; hazard ratios (HRs) vs zero activity included AF 0.68 (95% CI 0.58–0.79), HF 0.58 (0.47–0.71), MI 0.49 (0.24–1.00), and stroke 0.35 (0.12–0.99).
– CMR indices of cardiac remodeling (LV size and LV mass) showed similar relationships with MVPA in carriers and noncarriers. Higher MVPA was not associated with increased risk of malignant ventricular arrhythmias (VAs) in G+P- carriers.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Differential Physical Activity Responses to Diabetes Risk Reduction Interventions According to Prediabetes Phenotype: Insights from Pooled Randomized Controlled TrialsThe effectiveness of lifestyle interventions promoting physical activity for diabetes risk reduction varies by prediabetes phenotype, with individuals having impaired fasting glucose showing the least response. Tailored approaches may enhanSep 17, 2026Genotype-Dependent Risk and Impact of Atrial Fibrillation in Dilated Cardiomyopathy: Insights from the SHaRe RegistryThis study reveals genotype-specific differences in atrial fibrillation (AF) risk among dilated cardiomyopathy (DCM) patients, highlighting LMNA mutations as a major predictor of incident AF and its association with worse clinical outcomes,Sep 15, 2026Genetic Insights into Early Heart Failure Risk in Hypoplastic Left Heart Syndrome: Findings from the NC-DEFINE StudyA prospective study reveals that ultra-rare cardiomyopathy gene variants significantly increase risk for early heart failure in infants with hypoplastic left heart syndrome, highlighting potential for genetic risk stratification and precisiSep 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Expanding Horizons in Dilated Cardiomyopathy: A Comprehensive Genetic Reassessment in 2024The 2024 update of the Clinical Genome Resource elucidates a rapidly expanding genetic landscape for dilated cardiomyopathy, enhancing clinical genetic interpretation with 35 genes classified as high evidence, including nine novel discoveriSep 12, 2026
Navigating Rehabilitation During ECMO Support: Insights from a Retrospective Cohort StudyThis study explores rehabilitation initiation, progression, and physical activity levels in adult ECMO patients, highlighting early active rehabilitation feasibility and varied activity trajectories based on clinical goals.Sep 5, 2026
Left Atrial Dysfunction and Vutrisiran Efficacy in Transthyretin Amyloid Cardiomyopathy: Insights from the HELIOS-B TrialThis article reviews the prognostic role of left atrial dysfunction in transthyretin amyloid cardiomyopathy and evaluates vutrisiran’s impact on atrial function and clinical outcomes based on a secondary analysis of the HELIOS-B phase 3 triAug 21, 2026